Story · Medicine & Biotech
FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease Type C Live Longer
2 outlets · first reported by Patient Worthy on · latest · 30 hours of coverage
FDA approved Lembaz (adrabetadex) injection, the first treatment shown to help people with a severe form of Niemann-Pick disease type C (NPC) live longer. (FDA Press Announcements)
Coverage, in order
-
FDA Approves Roche’s Enspryng as First At-Home Injectable Treatment for Thyroid Eye Disease
As reported on PharmaBiz, the US Food and Drug Administration (FDA) has approved Roche’s Enspryng (satralizumab) for the treatment of adults with thyroid eye disease (TED), introducing the first subcutaneous therapy for the condition that can be self-administered at home or given by a caregiver…
-
FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease Type C Live Longer
FDA approved Lembaz (adrabetadex) injection, the first treatment shown to help people with a severe form of Niemann-Pick disease type C (NPC) live longer.
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.